1. Induced Disease Models Products Metabolic Enzyme/Protease Vitamin D Related/Nuclear Receptor Apoptosis
  2. Immunology and Inflammatory Disease Models RAR/RXR Apoptosis Endogenous Metabolite
  3. Hapten
  4. 9-cis-Retinoic acid

9-cis-Retinoic acid  (Synonyms: Alitretinoin)

Cat. No.: HY-15128 Purity: 99.92%
Handling Instructions Technical Support

9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities.

For research use only. We do not sell to patients.

CAS No. : 5300-03-8

Size Price Stock Quantity
Free Sample (0.1 - 0.2 mg)   Apply Now  
5 mg In-stock
10 mg In-stock
25 mg In-stock
50 mg In-stock
100 mg In-stock
200 mg   Get quote  
500 mg   Get quote  

* Please select Quantity before adding items.

This product is a controlled substance and not for sale in your territory.

Customer Review

Based on 5 publication(s) in Google Scholar

Other Forms of 9-cis-Retinoic acid:

Top Publications Citing Use of Products

    9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211.  [Abstract]

    MutuDC1940 cells were treated for 20 h with 1 μM 9-cis-Retinoic acid (9cRA), then subjected to Western blotting.

    9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211.  [Abstract]

    MutuDC1940 cells were treated for 20 h with 1 μM 9-cis-Retinoic acid (9cRA), then assayed for RALDH activity in the suspension cell format, utilising the indicated RAL concentrations for 20 min.

    9-cis-Retinoic acid purchased from MedChemExpress. Usage Cited in: J Biol Chem. 2026 Jan 29;302(3):111211.  [Abstract]

    mutuDC1940 cells were treated with 1 μM 9-cis-Retinoic acid (9cRA) for 20 hours (with or without), and then AldeRed retention assays were performed with or without 1 μM Win446 or 10 μM DEAB.

    View All RAR/RXR Isoform Specific Products:

    View All Endogenous Metabolite Isoform Specific Products:

    • Biological Activity

    • Purity & Documentation

    • References

    • Customer Review

    Description

    9-cis-Retinoic acid (ALRT1057), a vitamin A derivative, is a potent RAR/RXR agonist. 9-cis-Retinoic acid induces apoptosis, regulates cell cycle and has anticancer, anti-inflammatory and neuroprotection activities[1][2][3][4][5].

    IC50 & Target

    Human Endogenous Metabolite

     

    Cellular Effect
    Cell Line Type Value Description References
    CV-1 EC50
    0.2 μM
    Compound: 36, 9cRA
    Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay
    Transactivation of Gal4-LBD fused mouse RXRalpha (218 to 467) transfected in african green monkey CV1 cells assessed as luciferase activity at after 6 hrs by Dual-light chemiluminescent assay
    [PMID: 19216008]
    CV-1 EC50
    1.5 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR alpha
    [PMID: 11428923]
    CV-1 EC50
    100 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid X alpha receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    124 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma
    Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR gamma
    [PMID: 12482435]
    CV-1 EC50
    128 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta
    Transcriptional activation in CV-1 cells expressing mouse Retinoid X receptor RXR beta
    [PMID: 12482435]
    CV-1 EC50
    140 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor gamma using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    140 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid X gamma receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    191 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor alpha using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    191 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid alpha receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    195 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha
    Transcriptional activation in CV-1 cells expressing human Retinoid X receptor RXR-alpha
    [PMID: 12482435]
    CV-1 EC50
    200 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor beta using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    200 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid X beta receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    200 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR beta
    [PMID: 8709094]
    CV-1 EC50
    21 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR alpha
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR alpha
    [PMID: 11428923]
    CV-1 EC50
    219 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR gamma
    [PMID: 8709094]
    CV-1 EC50
    220 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR alpha
    [PMID: 12482435]
    CV-1 EC50
    250 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoid X receptor alpha using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    29 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR beta
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR beta
    [PMID: 11428923]
    CV-1 EC50
    29 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR beta
    [PMID: 12482435]
    CV-1 EC50
    3 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR beta
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR beta
    [PMID: 11428923]
    CV-1 EC50
    304 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR alpha
    [PMID: 8709094]
    CV-1 EC50
    316 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha
    Transcriptional activation in CV-1 cells expressing Retinoid X receptor RXR alpha
    [PMID: 8709094]
    CV-1 EC50
    4 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR gamma
    Transcriptional activation in CV-1 cells expressing retinoic acid receptor RAR gamma
    [PMID: 11428923]
    CV-1 EC50
    4.5 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma
    Transcriptional activation in CV-1 cells expressing retinoid X receptor RXR gamma
    [PMID: 11428923]
    CV-1 EC50
    45 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor gamma using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    45 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid gamma receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    50 nM
    Compound: 9-cis RA
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma
    Transcriptional activation in CV-1 cells expressing human Retinoic acid receptor RAR gamma
    [PMID: 12482435]
    CV-1 EC50
    50 nM
    Compound: 9-cis-RA
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
    Compound was tested for functional activity in CV-1 cells transfected with an expression vector for retinoic acid receptor beta using transactivation assay
    10.1016/0960-894X(95)00588-K
    CV-1 EC50
    50 nM
    Compound: 9-cis-RA
    Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
    Binding affinity against retinoic Acid beta receptors co-transfected into CV-1 cells
    [PMID: 8308867]
    CV-1 EC50
    52 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR beta
    [PMID: 8709094]
    CV-1 EC50
    74 nM
    Compound: 9-cis-RA
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
    Transcriptional activation in CV-1 cells expressing Retinoic acid receptor RAR gamma
    [PMID: 8709094]
    HEK-293T EC50
    1.09 μM
    Compound: 13
    Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay
    Partial agonist activity at recombinant human GAL4-DBD-fused LXRalpha-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay
    [PMID: 28169169]
    HEK-293T EC50
    1.73 μM
    Compound: 13
    Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay
    Partial agonist activity at recombinant human GAL4-DBD-fused LXRbeta-LBD expressed in HEK293T cells measured after 12 to 14 hrs by dual-glo luciferase reporter gene assay
    [PMID: 28169169]
    HEK293 EC50
    10 nM
    Compound: 9CisRA
    Agonist activity at human RXRalpha expressed in HEK293 cells by luciferase reporter gene assay
    Agonist activity at human RXRalpha expressed in HEK293 cells by luciferase reporter gene assay
    [PMID: 25305688]
    HEK293 EC50
    120 nM
    Compound: 9cRA
    Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay
    Agonist activity at Gal4-fused human RXR-alpha expressed in HEK293 cells assessed as receptor-mediated transcriptional activity treated 24 hrs after transfection measured 48 hrs post-transfection by dual luciferase reporter assay
    [PMID: 24801499]
    HL-60 EC50
    2 nM
    Compound: 9-cis RA
    Transglutaminase activity in HL-60 cdm-1 cells
    Transglutaminase activity in HL-60 cdm-1 cells
    [PMID: 7636843]
    HL-60 EC50
    2 nM
    Compound: 9-cis-RA
    Induction of transglutaminase (TGase) activity in HL-60 cells
    Induction of transglutaminase (TGase) activity in HL-60 cells
    [PMID: 8784454]
    In Vitro

    9-cis-Retinoic acid (1-10 μM; 0-5 days; CA 9-22 and NA cells) treatment significantly decreases proliferation in a dose-dependent manner in CA 9-22 and NA cells[1].
    9-cis-Retinoic acid (1 μM; 24 hours) treatment significantly increases PPARγ functional activity by >200% in CA 9-22 and NA aerodigestive cells[1].
    9-cis-Retinoic acid treatment results in the formation of a nuclear PPARγ-RXRα heterodimer supershift complex in CA 9-22 cells[1].
    9-cis-Retinoic acid inhibits proliferation and induces apoptosis in cutaneous T-cell lymphoma (CTCL) in a dose-dependent and time-dependent manner. 9-cis-Retinoic acid also induces G0/G1 cell cycle arrest by downregulation of cyclin D1. 9-cis-Retinoic acid significantly decreases phosphorylation of JAK1, STAT3, and STAT5 and downregulated Bcl-xL and cyclin D1[2].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Cell Proliferation Assay[1]

    Cell Line: CA 9-22 and NA cells
    Concentration: 1 μM, 10 μM
    Incubation Time: 0 day, 1 day, 3 days, 5 days
    Result: Significantly decreased proliferation.
    In Vivo

    9-cis-Retinoic acid (1 mg/kg; intravenous injection; daily; for 10 days; male C57BL/6J mice) treatment significantly decreases the serum ALT and AST level, alleviates hepatic necrosis of the bile duct ligation (BDL)-mice[3].

    MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

    Animal Model: Male C57BL/6J mice (6-8 weeks; 19-22 g) treatment with bile duct ligated[3]
    Dosage: 1 mg/kg
    Administration: Intravenous injection; daily; for 10 days
    Result: Significantly decreased the serum ALT and AST level, alleviated hepatic necrosis.
    Clinical Trial
    Molecular Weight

    300.44

    Formula

    C20H28O2

    CAS No.
    Appearance

    Solid

    Color

    White to yellow

    SMILES

    CC(/C=C/C(C(C)(CCC1)C)=C1C)=C/C=C/C(C)=C/C(O)=O

    Structure Classification
    Initial Source
    Shipping

    Room temperature in continental US; may vary elsewhere.

    Storage

    -20°C, protect from light, stored under nitrogen

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    Solvent & Solubility
    In Vitro: 

    DMSO : 25 mg/mL (83.21 mM; Need ultrasonic; Hygroscopic DMSO has a significant impact on the solubility of product, please use newly opened DMSO)

    Preparing
    Stock Solutions
    Concentration Solvent Mass 1 mg 5 mg 10 mg
    1 mM 3.3285 mL 16.6423 mL 33.2845 mL
    5 mM 0.6657 mL 3.3285 mL 6.6569 mL
    View the Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    • Molarity Calculator

    • Dilution Calculator

    Mass (g) = Concentration (mol/L) × Volume (L) × Molecular Weight (g/mol)

    Mass
    =
    Concentration
    ×
    Volume
    ×
    Molecular Weight *

    Concentration (start) × Volume (start) = Concentration (final) × Volume (final)

    This equation is commonly abbreviated as: C1V1 = C2V2

    Concentration (start)

    C1

    ×
    Volume (start)

    V1

    =
    Concentration (final)

    C2

    ×
    Volume (final)

    V2

    In Vivo:

    Select the appropriate dissolution method based on your experimental animal and administration route.

    For the following dissolution methods, please ensure to first prepare a clear stock solution using an In Vitro approach and then sequentially add co-solvents:
    To ensure reliable experimental results, the clarified stock solution can be appropriately stored based on storage conditions. As for the working solution for in vivo experiments, it is recommended to prepare freshly and use it on the same day.
    The percentages shown for the solvents indicate their volumetric ratio in the final prepared solution. If precipitation or phase separation occurs during preparation, heat and/or sonication can be used to aid dissolution.

    • Protocol 1

      Add each solvent one by one:  10% DMSO    40% PEG300    5% Tween-80    45% Saline

      Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 400 μL PEG300, and mix evenly; then add 50 μL Tween-80 and mix evenly; then add 450 μL Saline to adjust the volume to 1 mL.

      Preparation of Saline: Dissolve 0.9 g sodium chloride in ddH₂O and dilute to 100 mL to obtain a clear Saline solution.
    • Protocol 2

      Add each solvent one by one:  10% DMSO    90% (20% SBE-β-CD in Saline)

      Solubility: 2.5 mg/mL (8.32 mM); Suspended solution; Need ultrasonic

      This protocol yields a suspended solution of 2.5 mg/mL. Suspended solution can be used for oral and intraperitoneal injection.

      Taking 1 mL working solution as an example, add 100 μL DMSO stock solution (25.0 mg/mL) to 900 μL 20% SBE-β-CD in Saline, and mix evenly.

      Preparation of 20% SBE-β-CD in Saline (4°C, storage for one week): 2 g SBE-β-CD powder is dissolved in 10 mL Saline, completely dissolve until clear.
    In Vivo Dissolution Calculator
    Please enter the basic information of animal experiments:

    Dosage

    mg/kg

    Animal weight
    (per animal)

    g

    Dosing volume
    (per animal)

    μL

    Number of animals

    Recommended: Prepare an additional quantity of animals to account for potential losses during experiments.
    Please enter your animal formula composition:
    %
    DMSO +
    +
    %
    Tween-80 +
    %
    Saline
    Recommended: Keep the proportion of DMSO in working solution below 2% if your animal is weak.
    The co-solvents required include: DMSO, . All of co-solvents are available by MedChemExpress (MCE). , Tween 80. All of co-solvents are available by MedChemExpress (MCE).
    Calculation results:
    Working solution concentration: mg/mL
    Method for preparing stock solution: mg drug dissolved in μL  DMSO (Stock solution concentration: mg/mL).

    *In solvent : -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen)

    The concentration of the stock solution you require exceeds the measured solubility. The following solution is for reference only. If necessary, please contact MedChemExpress (MCE).
    Method for preparing in vivo working solution for animal experiments: Take μL DMSO stock solution, add μL . μL , mix evenly, next add μL Tween 80, mix evenly, then add μL Saline.
     If the continuous dosing period exceeds half a month, please choose this protocol carefully.
    Please ensure that the stock solution in the first step is dissolved to a clear state, and add co-solvents in sequence. You can use ultrasonic heating (ultrasonic cleaner, recommended frequency 20-40 kHz), vortexing, etc. to assist dissolution.
    Purity & Documentation

    Purity: 99.92%

    References

    Complete Stock Solution Preparation Table

    * Please refer to the solubility information to select the appropriate solvent. Once prepared, please aliquot and store the solution to prevent product inactivation from repeated freeze-thaw cycles.
    Storage method and period of stock solution: -80°C, 6 months; -20°C, 1 month (protect from light, stored under nitrogen). When stored at -80°C, please use it within 6 months. When stored at -20°C, please use it within 1 month.

    Optional Solvent Concentration Solvent Mass 1 mg 5 mg 10 mg 25 mg
    DMSO 1 mM 3.3285 mL 16.6423 mL 33.2845 mL 83.2113 mL
    5 mM 0.6657 mL 3.3285 mL 6.6569 mL 16.6423 mL
    10 mM 0.3328 mL 1.6642 mL 3.3285 mL 8.3211 mL
    15 mM 0.2219 mL 1.1095 mL 2.2190 mL 5.5474 mL
    20 mM 0.1664 mL 0.8321 mL 1.6642 mL 4.1606 mL
    25 mM 0.1331 mL 0.6657 mL 1.3314 mL 3.3285 mL
    30 mM 0.1109 mL 0.5547 mL 1.1095 mL 2.7737 mL
    40 mM 0.0832 mL 0.4161 mL 0.8321 mL 2.0803 mL
    50 mM 0.0666 mL 0.3328 mL 0.6657 mL 1.6642 mL
    60 mM 0.0555 mL 0.2774 mL 0.5547 mL 1.3869 mL
    80 mM 0.0416 mL 0.2080 mL 0.4161 mL 1.0401 mL
    • No file chosen (Maximum size is: 1024 Kb)
    • If you have published this work, please enter the PubMed ID.
    • Your name will appear on the site.
    Help & FAQs
    • Do most proteins show cross-species activity?

      Species cross-reactivity must be investigated individually for each product. Many human cytokines will produce a nice response in mouse cell lines, and many mouse proteins will show activity on human cells. Other proteins may have a lower specific activity when used in the opposite species.

    Your Recently Viewed Products:

    Inquiry Online

    Your information is safe with us. * Required Fields.

    Product Name

     

    Requested Quantity *

    Applicant Name *

     

    Salutation

    Email Address *

     

    Phone Number *

    Department

     

    Organization Name *

    City

    State

    Country or Region *

         

    Remarks

    Bulk Inquiry

    Inquiry Information

    Product Name:
    9-cis-Retinoic acid
    Cat. No.:
    HY-15128
    Quantity:
    MCE Japan Authorized Agent: